Press Releases

Sep 13, 2021 6:00am EDT

Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Sep 09, 2021 6:00am EDT

Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

Sep 07, 2021 6:00am EDT

Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference

Jun 08, 2021 6:00am EDT

Greenwich LifeSciences Set to Join Russell 2000® Index

Jun 07, 2021 6:30am EDT

Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated

Apr 19, 2021 10:30am EDT

Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization

Apr 14, 2021 6:00am EDT

Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting

Apr 12, 2021 5:52am EDT

REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

Apr 10, 2021 4:13pm EDT

Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

Apr 09, 2021 5:00am EDT

Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up